Study of EVO756 in Adults With Migraine

Mean change from baseline in the number of MMD

Time frame: Weeks 4, 8, and across the treatment period (up to 12-weeks)

Mean change from baseline in the number of monthly headache days (MHD)

Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

Proportion of subjects achieving ≥50% and ≥75% reduction in MMD

Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

Proportion of subjects achieving ≥50% and ≥75% reduction in MHD

Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

Mean change from baseline in monthly acute migraine medication use days

Time frame: Weeks 4, 8, 12, and across the treatment period (up to 12-weeks)

Occurrence of treatment emergent adverse events (TEAE) and serious adverse events (SAE)

Time frame: through Week 16